Dr Reddys Laboratories Ltd Q2 FY2024 Concall Summary

Key Takeaways

• Steady quarter, execution-led: Consolidated revenue grew 9% YoY with US and Europe generics driving the beat, while India showed early signs of a planned turnaround.
• US growth story intact despite noise: Base business volume expansion and Mayne integration more than offset price erosion; management flagged 25–30 launches on track for the year.
• Biosimilars are the long game: The Bachupally facility received a UK GMP certificate but also nine US FDA observations; management called them addressable and pointed to a FY27 onwards ramp-up for the pipeline.
• Margins held the line: Gross margin dipped only ~40 bps YoY despite cost inflation, while SG&A rose on brand and digital investments; the full-year SG&A guide is 28–29% of sales.
• What to watch next quarter: Resolution of the US FDA observations, the pace of India’s exit toward double-digit growth, and any update on the Mayne portfolio’s customer discussions.

US Generics: Volume Offsets Price Erosion

• Growth engine: North America grew 9% YoY, driven by market share expansion in existing key products and the full integration of the Mayne portfolio.
• Price erosion is stable, not broad: Erosion affects only products entering a bid or RFP in a given quarter; management described this year’s erosion as more moderate than in other years and fluctuating between high single digits and low double digits.
• Volume and portfolio doing the work: Most of the sequential revenue growth came from volume growth and the Mayne portfolio, not from one-off pricing events.
• Shortage opportunities persist: The US team continues to capture short-term contracts and shortage situations by prioritizing continuity, service and sustainability of supply.
• Launch cadence confirmed: 25 to 30 launches remain on track for this year, with an equal number of material products already identified for FY25, FY26 and FY27.
• Revlimid contribution undisclosed: Management declined to discuss quantities or confirm whether Revlimid sales changed materially quarter-on-quarter, reiterating only that growth came from the base business and Mayne.

Israeli: "I believe that those observations are addressable. We are going to address all of them in the beginning of November. Some of them will require us to create a CAPA, which means we need to produce certain product for a certain period of time in order to show certain consistency of data, which will take us to January. But overall, I believe that this is addressable."

India: A Turnaround Under Construction

• Modest headline, better underneath: India grew 3% YoY; excluding the loss of revenues from NLEM-related price reductions, growth was in the mid-single digits.
• Two deliberate choices: Management trimmed the base portfolio by divesting brands and is now focused on profitable growth and sales and marketing execution, which is driving gradual improvement.
• Chronic therapies are the wedge: Chronic products now represent 35% of the India business and will grow as more chronic launches come through, a mix shift that should lift both growth and margins over time.
• Innovation pipeline converting: Products from in-licensing deals signed roughly a year ago are now launching; the typical cycle from deal signing to product approval is 12 to 18 months, longer when clinical trials are required.
• Margin advantage: India is a branded generics market and carries a better margin profile than the unbranded US and Europe businesses, a structural advantage management intends to protect.
• Sales force productivity over expansion: No immediate need to increase the sales force; the focus is on improving productivity and coverage, with additions only if required.

Israeli: "I believe that in the end of the year, we should see double-digit growth and continue in the quarters after."

Biosimilars: Building the FY27 Ramp

• Regulatory milestone, with work to do: The Bachupally biologics facility received a GMP certificate from the UK MHRA, but a US FDA pre-approval inspection concluded with nine observations. Management expects to address all observations by November, with some CAPA work extending into January.
• Pipeline depth: Five Phase-III biosimilars are slated for global launch including the US in the next two years or so, with the main revenue ramp-up expected from FY27 onwards.
• Rituximab filing progressing: The biosimilar Rituximab was submitted in April, a pre-approval inspection has been received, and the answer is due by November; launch in the US and Europe is expected at the beginning of FY25.
• Emerging markets are the current beachhead: Most biosimilar activity today is in India, Russia and other emerging markets with products like Rituximab, and that activity is ramping up.
• Pegfilgrastim is a royalty play only: The product is not Dr. Reddy’s own; it was part of an arrangement with Merck Serono and Fresenius, and the company receives only a royalty, which management described as not a big amount.
• Commercial build-out ahead: For products launching from FY27 onwards, the company will need to build a dedicated sales force, a cost that will phase in closer to launch.

Israeli: "The main ramp-up in biosimilars for us will be probably from FY27 onwards."

Europe and Emerging Markets: Steady Contributors

• Europe delivered 12% YoY growth: Driven by new product launches and volume improvement in the base business, more than offsetting price erosion; injectables and tender wins were the primary growth drivers.
• More markets, more tenders: Growth is coming from broader market participation and an increasing number of tender wins, not just a few large contracts.
• Emerging markets dipped marginally: A 1% YoY decline was attributed to seasonality and unfavorable forex; the full-year outlook remains on track.
• Russia grew in constant currency: Up 4% YoY and 9% sequentially in constant currency; like India, Russia is a branded generics market with a healthy margin profile.
• China approvals accelerating: Six approvals have now been secured, with the pace picking up since April; most products are among the first wave and normally among the first three to market, and the portfolio should start contributing meaningfully from next fiscal.

Margins, Investment and Capital Allocation

• Gross margin held broadly flat sequentially: Consolidated gross margin decreased ~40 bps YoY; Global Generics stood at 63.6% and PSAI at 17.8%.
• SG&A rose on deliberate investment: Spend increased 13% YoY and 6% QoQ, driven by investments behind brands, digitalization in the front end, R&D and manufacturing facilities; the full-year guide is 28–29% of sales.
• R&D spend to grow moderately: Driven by ongoing clinical trials on differentiated assets and developmental efforts for small molecules and the biosimilars pipeline; as a percentage of sales, R&D should stay in the current range or move slightly higher.
• Tax rate benefit structural: The lower effective tax rate versus the prior year is mainly due to the adoption of corporate tax rates under Section 115BAA; the normalized ETR is expected in the 24–25% range for the full year.
• Working capital improved: Operating working capital reduced by Rs. 598 crores, mainly due to a decrease in receivables, which management described as a normal function of credit period and order cycles.
• M&A appetite is disciplined: The company is looking for deals of all sizes but is not in a rush; the focus is on complementary activities for the organic strategy, not transformative deals.

Agarwal: "I would say 2x EBITDA is what we will be willing to go for. Beyond that, we would not like to take a financial risk."

Guidance & Commitments

Key Metrics